Wijnegem, Belgium, July 26th 2016: Novosanis announced today their collaboration with ImevaX, a biopharmaceutical company based in Munich, Germany. ImevaX developed a vaccine against the pathogen Helicobacter pylori (H. pylori) that can cause chronic stomach sores and ulcers potentially leading to gastric cancer. Novosanis will supply the VAX-ID™ device that allows for a standardized and accurate injection of the vaccine for their clinical trials.
Munich (Germany), October 28, 2015: ImevaX GmbH, a specialist in developing vaccines against pathogens of chronic infectious diseases, especially H. pylori infections, announced today the appointment of Dr Marie Roskrow as Chief Executive Officer and Staph Leavenworth Bakali as Chairman of the Supervisory Board.
Munich (Germany): ImevaX GmbH, a specialist in vaccines against pathogens of chronic infectious diseases, especially in H. pylori infections, announced today that KfW has joined the company’s 2014 Series A investor syndicate through a second closing of the financing.